UBS AM
CGON icon

UBS AM’s CG Oncology CGON Stock Holding History

UBS AM’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1M Sell
761,807
-303,159
-28% -$19.8M 0.01% 640
2026
Q1 		$72.1M Sell
1,064,966
-25,928
-2% -$1.47M 0.02% 562
2025
Q4 		$45.3M Buy
1,090,894
+310,592
+40% +$12.9M 0.01% 628
2025
Q3 		$31.4M Sell
780,302
-76,295
-9% -$2.22M 0.01% 692
2025
Q2 		$22.3M Buy
856,597
+677,234
+378% +$16.3M ﹤0.01% 1010
2025
Q1 		$4.39M Buy
179,363
+53,461
+42% +$1.5M ﹤0.01% 1639
2024
Q4 		$3.61M Buy
125,902
+104,780
+496% +$3.58M ﹤0.01% 1764
2024
Q3 		$797K Sell
21,122
-2,503
-11% -$87.7K ﹤0.01% 2488
2024
Q2 		$746K Buy
+23,625
New +$819K ﹤0.01% 2504

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's CGON Position: Q2 2026 in Review

UBS AM reduced its CG Oncology (CGON) stake by 28% in Q2 2026, selling an estimated $19.8M and leaving 761,807 shares worth $54.1M. The position accounts for 0.01% of the portfolio, ranked #640.

UBS AM first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $72.1M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • UBS AM held 761,807 shares of CG Oncology worth $54.1M as of Q2 2026.
  • UBS AM sold 303,159 CG Oncology shares in Q2 2026, an estimated $19.8M.
  • CG Oncology made up 0.01% of UBS AM's portfolio in Q2 2026, its #640 holding.
  • UBS AM first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • UBS AM's CG Oncology position peaked at $72.1M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.